Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 27;13(21):1779.
doi: 10.3390/cells13211779.

Myeloid-Derived Suppressor Cells in Bladder Cancer: An Emerging Target

Clément Klein  1   2   3 , Samy Mebroukine  1   2   3 , Mathilde Madéry  1   3 , Alexandra Moisand  1   3 , Thomas Boyer  1   3 , Nicolas Larmonier  1   3 , Grégoire Robert  1   2   3 , Charlotte Domblides  1   3   4
Affiliations
Review

Myeloid-Derived Suppressor Cells in Bladder Cancer: An Emerging Target

Clément Klein et al. Cells. .

Abstract

Bladder cancer remains a prevalent and challenging malignancy. Myeloid-derived suppressor cells (MDSCs) have emerged as key contributors to the immunosuppressive tumor microenvironment, facilitating tumor progression, immune evasion, and resistance to therapies. This review explores the role of MDSC in bladder cancer, highlighting their involvement in immune regulation; tumor progression; and resistance to therapies such as bacillus Calmette-Guérin (BCG) therapy, chemotherapy, and immune checkpoint inhibitors (ICIs). We also discuss their potential as biomarkers and therapeutic targets, with current evidence suggesting that targeting MDSCs, either alone or in combination with existing treatments such as BCG and ICIs, may enhance anti-tumor immunity and improve clinical outcomes. However,, challenges remain, particularly regarding the identification and therapeutic modulation of MDSC subpopulations. Further research is warranted to fully elucidate their role in bladder cancer and to optimize MDSC-targeted therapies.

Keywords: biomarker; bladder cancer; immune inhibition; immunotherapy; myeloid-derived suppressor cells; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Gontero P., Birtle A., Compérat E., Escrig J.L.D., Liedberg F., Mariappan P., Masson-Lecomte A., Mostafid A.H. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). Invasive Bladder Cancer. 2024. [(accessed on 24 October 2024)]. Available online: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer. - PubMed
    1. Sylvester R.J., Van Der Meijden A.P.M., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., Newling D.W.W., Kurth K. Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. Eur. Urol. 2006;49:466–477. doi: 10.1016/j.eururo.2005.12.031. - DOI - PubMed
    1. Cambier S., Sylvester R.J., Collette L., Gontero P., Brausi M.A., Van Andel G., Kirkels W.J., Silva F.C.D., Oosterlinck W., Prescott S., et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin. Eur. Urol. 2016;69:60–69. doi: 10.1016/j.eururo.2015.06.045. - DOI - PubMed
    1. Witjes J.A., Bruins H.M., Carrión A., Cathomas R., Compérat E.M., Efstathiou J.A., Fietkau R., Gakis G. Muscle-invasive and Metastatic Bladder Cancer. 2024. [(accessed on 24 October 2024)]. Available online: https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer.
    1. Sylvester R.J., Van Der Meijden A.P.M., Lamm D.L. Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials. J. Urol. 2002;168:1964–1970. doi: 10.1016/S0022-5347(05)64273-5. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources